Part-Time Clinical Pharmacy

DEBORAH L. WILLIS, R.Ph.

**** ****** **** ****, *******, TX 75783 903-***-****

OBJECTIVE

Help people make the best use of medications thereby enhancing patients’ health-related quality of life.

EDUCATION & TRAINING

LeTourneau University, Business Administration, Masters Program, 2005-

B.Pharm. University of Iowa, May 1981

University of Iowa Hospitals & Clinics, internship

University of Missouri, pre-pharmacy

INTERNATIONAL EXPERIENCE

As a volunteer for Mercy Ships, a humanitarian organization operating hospital ships in developing nations, I was responsible for securing supplies/medications for surgeries and clinics, inventory management and readying supplies for crating/shipping from the organization’s international operations center in Lindale, Texas. My responsibilities included coordinating with ships’ medical teams to determine list of supplies/medications needed and contacting medical supply manufacturers and pharmaceutical companies to obtain goods in time for ships’ docking.

CAREER SKILLS/KNOWLEDGE

Pharmacy operations hospital and retail

Medication therapy management

Face to face teaching skills and experience, group presentations and individual tutoring

Study design, qualitative and quantitative research techniques

Customer relations

Leadership and project management

Inventory management

Staff supervision/development/training

Team building

Program development

Continuous quality improvement

Drug utilization review

Maintaining drug distribution records

Writing policy and procedure

Medical writing

CAREER ACHIEVEMENTS

Clinical Pharmacy Specialist

Critical Care (Cardiac, Surgical, Medical) Pharmacy

Cancer/Bone Marrow Transplant Pharmacy

·developed clinical monitoring programs for Critical Care & Bone Marrow Transplant

·Presented at state association meeting, internationally published paper & presented at national convention

·ACLS Instructor, nursing & pharmacy educator

Assistant Director, Hospital Pharmacy

·inter-discipline committee member

·problem-solving with department heads and administration

·supervision and training of pharmacy staff

Clinical Research Scientist

·design Serious Adverse Reaction reporting system utilized by several departments

·timely reporting to government agency, FDA

·interaction with Pharmaceutical Company Representatives

·present updates at board meeting

·supervise and train department staff

·work directly with physician investigators

·programs designed and implemented improving quality & communication,

saving time & cost, as well as revenue-generating.

Coordinator, Medical Writing

·protocols and study materials developed

·FDA Investigational New Drug Applications & reports prepared

·study analysis data entry and flowsheets prepared

·coordinate writing and submission of manuscript for publication with

physicians and pharmaceutical companies

·design of poster for international physician’s convention

·editor for monthly company-sponsored journal

·computer and typing skills:

WordPerfect, Microsoft Word, Lotus, Page Maker, Paradox, SAS

Pharmacy Manager Retail Store

·manage inventory

·pharmaceutical-care consultations

·hire, train, direct and promote pharmacy staff

·handle customer complaints

SAMPLE PROGRAMS IMPLEMENTED

Improving Communication

Document design for “Fast-Stat” study summary sheet.

File created for Educational Information/Study Results.

Improving Quality

Program development for Peer Review of Publications.

Time-Saving

Standard form & reporting program design for “Serious Adverse Event” saving nursing staff time

Form design for patients “Off-Study” saving data entry time

On-Line master office rolodex saving office staff time

Revenue-Generating

Analysis & manuscript for: Retrospective analysis of infectious disease in patients who received leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer.

Protocol development for: A survey trial to determine the feasibility of utilizing bioelectrical impedance analysis (BIA) as a clinical measure of lean body mass (LBM) in cancer patients receiving chemotherapy.

Protocol development, analysis and manuscript for: The effects of Agrelin (anagrelide HCl) on circulating cytokine levels in patients with thrombocythemia.

Research Grant application for analysis and manuscript: Treatment IND of Gemzar (gemcitabine) for patients with pancreatic cancer.

CAREER PLACEMENTS & APPOINTMENTS

1981 Community Pharmacist, Rene’s Drug Store, Taylorville, IL

1982 – 1984 Staff Pharmacist, Veteran's Administration Hospital, Long Beach, CA

1984 – 1986 Staff Pharmacist, Veteran's Administration Hospital, Tampa, FL

1986 – 1987 Clinical Pharmacist: Pharmacokinetic Monitoring, West Florida Regional Hospital, Pensacola, FL

1987 – 1990 Clinical Pharmacy Specialist: Emergency Medicine, Critical Care Cardiac/Surgical/Medical, Mother Frances Hospital, Tyler, TX

ACLS Instructor, Instructor of Pharmacology (guest)

Tyler Junior College

School of Nursing & EMT Training

1990 – 1992 Assistant Director of Pharmacy, Memorial Hospital, Palestine, TX

1992 Consultant Pharmacist, Baylor University Medical Center, Gilmer, TX

1992 – 1994 Clinical Pharmacy Specialist: Bone Marrow Transplant, Baylor University Medical Center, Dallas, TX

1994 – 1996 Clinical Research Scientist, Coordinator Medical Writing, Texas Oncology, P. A. Dallas, TX

1996 – 1999 Pharmacy Manager, Eckerd Drug, Tyler, TX

1999 – 2000 Staff Pharmacist, Henderson Memorial Hospital, Henderson, TX

2000 – 2002 Staff Pharmacist, Albertsons, Tyler, TX

2002 – 2004 Pharmacy Manager, Walgreens, Tyler, TX

2004 – 2009 Pharmacy Manager, Brookshire Grocery Company, Mineola, TX

2010 – Pharmacy Assistant Manager, Kroger, Longview, TX

ARTICLES AND RESEARCH

Presentations & Posters

1. Willis D: A critical analysis of the intensive-care pharmacy experience. Slide Presentation. Amer Soc Hosp Pharm, Midyear Clinical Meeting, Atlanta, Georgia, 1989.

2. Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, Applebaum F: Retropsective analysis of infectious disease in patients who received leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer. Amer Soc Hematol, 37th Annual Meeting, Seattle, Washington, Poster #871, Dec 1995.

3.Richards DA, Cox JV, Kimmel GT, Hyman WJ, Freed MI, Martin DE, Jordasky DK, Brocks DR, Levitt B, Willis DL and Nemunaitis J: A phase I trial of SK&F 107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies. Slide Presentation. Texas Oncology, P.A., Protocol Meeting, Dallas, Texas, Mar 1996.

Publications

1. Berg MJ, Ebert B, Willis DK, Host T, Fincham RW, Schottelius DD: Parkinsonism - drug treatment: part II. Drug Intell Clin Pharm 21(2):167-72, Feb 1987.

2. Willis, DL: The code response team: a stepping stone to clinical involvement. Texas Soc Hosp Pharm J, 1988.

3. Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, Applebaum F: Retropsective analysis of infectious disease in patients who received leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer. Abstract. Blood 86(10 Suppl 1):220a,871, 1995.

Submitted For Publication

1. Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, Applebaum F: Retrospective analysis of infectious disease in patients who received leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer. Bone Marrow Transplant (submitted for publication, Feb 6, 1996).

2. Gordon AN, Stringer CA, Matthews CM, Willis DL, and Nemunaitis J: Phase I dose escalation of taxol in patients with advanced ovarian cancer receiving cisplatin. (submitted for publication, Apr 1, 1996).

3. Nemunaitis J, Pineiro L, Savin M, Richards D, Willis DL and Ando D: Macrophage Colony-stimulating Factor (M-CSF) in the Treatment of Invasive Fungal Infection in Cancer Patients, with Pharmacokinetic Assessment. Brief Report (submitted for publication, Apr 4, 1996).

4. Gordon A, Stringer CA, Matthews C, Hancock K, Willis DL, Nemunaitis J: A phase I/II dose escalation study of carboplatin with paclitaxel as first line treatment for stage III/IV ovarian cancer. Abstract. (submitted for publication May 15, 1996).

Manuscripts and Abstracts in Preparation:

1. Nemunaitis J and Willis DL: A comparative review of the clinical pharmacology and efficacy of the colony-stimulating factors. (manuscript in preparation).

2. Richards DA, Cox JV, Kimmel GT, Hyman WJ, Freed MI, Martin DE, Jordasky DK, Brocks DR, Levitt B, Willis DL and Nemunaitis J: A phase I trial of SK&F 107647: a synthetic hematoregulatory peptide in patients with solid tumor malignancies. (manuscript in preparation).

3. Gordon AN, Stringer CA, Matthews CM, Willis DL, and Nemunaitis J: Carboplatin/Taxol dose escalation study in ovarian cancer. (abstract in preparation) (analysis in progress)

4. Kerr, Denham, Willis DL and Nemunaitis J: Gemcitabine in Pancreatic CA (manuscript in preparation) (analysis in progress)

5. Cooper, Willis DL and Nemunaitis J: Anagrelide for the treatment of thrombocythemia (analysis in progress)

Articles for “Discover”

1. Willis D: Blood progenitor cells, a new FDA-approved indication for two hematopoietic growth factors: research directions in TOPA. Discover 4(2), Feb 1996.

2. Nemunaitis J, Willis D: Historical perspective on colon cancer. Discover 4(3), Mar 1996.

3. Willis D: Mouse antibody in colon cancer therapy: Panorex®. Discover 4(4), Apr 1996.

4. Willis D: Strong PRN Representation in Philadelphia, ASCO 1996. Discover 4(5), May 1996.

5. Nemunaitis J, Tong A, Cooper B, Willis D: Anagrelide for Thrombocythemia: How does it work? Discover 4(5), May 1996.

6. Willis D: ODAC Recommends Approval of Topotecan. Discover 4(5), May 1996.

Fast-Stat Sheets for TOPA/PRN Studies:

1. Cox J, Nemunaitis J: Results from TOPA's participation in the phase II study CPT-11 (irinotecan) in 5-FU-refractory metastatic colorectal cancer. (Study #94-10, prepared Jun 1995, Willis D) Discover 3(9), Sep 1995.

2. Nemunaitis J: Study results of randomized trial of breast cancer patients receiving HDAC + G-CSF with vs without PBSC; G-CSF mobilized, CS-3000® Plus blood cell separator, outpatient. (Study #94-15, prepared Oct 1995, Willis D).

3. Gordon A, Nemunaitis J: Phase I, intra-topa study: results of dose escalation of Taxol with cisplatin in advanced ovarian cancer. (Study #93-27, prepared Jan 1996, Willis D) Discover 4(2), Feb 1996.

4. Richards D, Cox J, Nemunaitis J: Phase I, intra-topa study: results of SK&F 107647 in refractory cancers. (Study #93-39, prepared Jan 1996, Willis D) Discover 4(4), Apr 1996.

Study Analysis (flowsheets and/or data entry into Paradox+SAS Programming)

1. Willis D, Rosenfeld C, Meyer W: Study 93-03 (61 patients). Phase I/II, randomized, open label trial to evaluate the safety, tolerability, and biological effects of SDZ ILE 964 (recombinant human interleukin-3) compared to sequential and combination administration of SDZ ILE 964 and leukine or neupogen for mobilization of peripheral blood progenitor cells for autologous transplant in patients with lymphoid malignancies or breast cancer. Jul 1995.

2. Willis D, Meyer W: Retrospective Study. Donor leukocyte infusion (DLI) for post-bone marrow transplant (BMT) relapse - retrospective cohort analysis of 141 cases. Interim Analysis, Aug 1995.

3. Willis D, Meyer W: Study #94-10 (43 patients). Phase II trial of irinotecan hydrochloride (CPT-11) for patients with 5-FU-refractory colorectal cancer. Interim Analysis, Jun 1995.

4. Willis D, Meyer W: Study #93-27 (23 patients). A phase I/II dose escalation study of taxol and cisplatin with filgrastim support in the treatment of ovarian cancer patients with advanced disease. Interim Analysis, Sep 1995; Final Analysis Jan 1996.

5. Willis D, Meyer W: Study #95-15 (10 patients). Peripheral blood stem cells (PBSC) or isolated CD34+ cells from mobilized peripheral stem cell collections for hematologic rescue of advanced breast cancer patients treated with high-dose chemotherapy. Oct 1995.

6. Willis D, Meyer W: Retrospective (140 patients). Retrospective analysis of infectious disease in patients who received leukine versus patients not receiving a cytokine who underwent autologous bone marrow transplant (ABMT) for treatment of lymphoid cancer. Nov 1995.

7. Willis D: Study #93-39 (16 patients), Evaluation of the safety, tolerability, and preliminary pharmakokinetics and pharmacodynamics of single, rising, intravenous doses of SK&F 107647 in patients with non-lymphoid solid tumor malignancies. Dec 1995.

8. Willis D: Study #93-02 (6 patients), Open study of recombinant M-CSF and antifungal therapy in patients with definitive or probable invasive candida or aspergillus fungal infections. Feb 1996.

9. Willis D, Meyer W: Study #94-02 (64 patients). An open protocol for the use of Agrelin (anagrelide HCl) for patients with thrombocythemia. Interim Analysis (16 patients) Feb 1996. (analysis in progress)

10. Willis D: Study #94-43 (22 patients). Phase I/II, dose escalation study of carboplatin in treatment of newly diagnosed ovarian cancer patients with advanced disease receiving taxol. Mar 1996. (analysis in progress)

11. Willis D: Study #95-18 & #95-18C (82 patients). Treatment IND of Gemzar (gemcitabine) for patients with pancreatic cancer. Apr 1996. (analysis in progress)

Protocols and Study Materials Developed

1. Randomized phase III trial comparing peripheral blood stem cells mobilized with G-CSF to G-CSF alone in patients receiving dose-intensive chemotherapy for treatment of advanced malignancy. Protocol. (Study #94-15A)

2. Phase I/II, dose escalation study of carboplatin in treatment of newly diagnosed ovarian cancer patients with advanced disease receiving taxol. Protocol. (Study #94-43)

3. Chemo immunotherapy of metastatic renal cell carcinoma with IL-2, INF-alpha2B and 5-fluorouracil. Case Report Forms & Patient Diary. (Study #95-07)

4. Phase II trial of estramustine and paclitaxel versus estramustine and vinblastine in hormone refractory prostate cancer. Protocol. Oct 1995.

5. Amendment: Outpatient transplant for local regional breast cancer. Protocol. Mar 1996. (protocol in development)

6. A survey trial to determine the feasibility of utilizing bioelectrical impedance analysis (BIA) as a clinical measure of lean body mass (LBM) in cancer patients receiving chemotherapy. Protocol Concept, Protocol & Case Report Forms. Apr 1996. (protocol in development)

7. The effects of Agrelin (anagrelide HCl) on circulating cytokine levels in patients with thrombocythemia. Protocol Concept. Apr 1996. (protocol in development)

FDA Investigational New Drug Applications & Reports

1. Investigator-Sponsor BB-IND 4866

Phase I/II, Randomized, Open Label Trial to Evaluate the Safety, Tolerability, and Biological Effects of Administration of SDZ ILE 964 and Leukine or Neupogen for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplant in Patients with Lymphoid Malignancies or Breast Cancer.

2. Investigator-Sponsor BB-IND 3658

Hematopoietic Stem Cell Transplantation Using Cells Cryopreserved in Dimethylsulfoxide and Pentastarch Without a Rate Controller.

3. Investigator-Sponsor BB-IND 6251

Randomized Phase III Trial Comparing Peripheral Blood Stem Cells Mobilized with G-CSF Alone in Patients Receiving Dose-Intensive Chemotherapy for Treatment of Advanced Malignancy.

4. Investigator-Sponsor BB-IND 46,651

A Phase I/II Dose Escalation Study of Carboplatin in the treatment of Newly Diagnosed Ovarian Cancer Patients With Advanced Disease Receiving Taxol.

DEBORAH L. WILLIS, R.Ph.

Contact this candidate